Treatment of diabetic ketoacidosis: should mode of insulin administration dictate use of intensive care facilities?
Haas
Romana M
RM
Hoffman
Andrew R
AR
D003362:Cost-Benefit Analysis; D016883:Diabetic Ketoacidosis / Q000188:drug therapy* / Q000191:economics; D016903:Drug Monitoring; D017722:Hospital Charges / Q000706:statistics & numerical data; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000191:economics; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000191:economics; D007362:Intensive Care Units / Q000191:economics / Q000706:statistics & numerical data*; D018579:Patient Selection; D012449:Safety; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D007328:Insulin